Palmoplantar Psoriasis Complete Clearance Is Achieved Rapidly And Sustained With Ixekizumab Treatment In Adult And Pediatric Patients With Moderate-To-Severe Plaque Psoriasis

The study analyzed the effectiveness of ixekizumab in achieving and sustaining complete clearance of palmoplantar psoriasis in both adult and pediatric patients with moderate-to-severe plaque psoriasis over several years. The analysis included data from six trials with a total of 256 patients. Results showed that by week 4, a significant proportion of adult patients achieved complete clearance, with response rates ranging from 38.9% to 52.9% across different trials. This clearance was sustained through 1 year in most trials and up to 5 years in some, with rates as high as 96.6%. In the pediatric population, the response rate increased from 21.4% at week 4 to 90.0% by week 108. The study concludes that ixekizumab leads to rapid and sustained improvement in palmoplantar psoriasis for both adults and children, although the small sample size for pediatric patients should be considered.